Biotech News
Filter News
Found 481,057 articles
-
Nicole Fevrier Davis Opens New MindBody Mastery Studio and Adds Psychic Assessments and Neurofeedback to her List of Unique Fitness Training Services
5/1/2018
Psychic personal trainer Nicole Fevrier Davis is slated to open her new studio at 10 Roberts Lane in Ridgefield CT on May 2nd.
-
Most investors thought 2018 would be a big year for mergers and acquisitions in the biopharma industry because of changes to the tax law, and so far they’ve been right.
-
Celgene Corporation and Evotec AG announced they have inked a long-term strategic partnership to find and develop new cancer drugs.The partnership will lean on Evotec’s preclinical discovery and development platforms.
-
With a new chief executive officer on board, GRAIL, Inc. has secured a whopping $300 million in an oversubscribed Series C financing round led by multiple Chinese investment groups.
-
AstraZeneca has a problem. Not with its pipeline, but with the way a significant chunk of shareholders views its executive pay program.
-
Shares of newly dubbed Sesen Bio (formerly Eleven Biotherapeutics) have plunged 23 percent after the company released positive, three-month data from its ongoing Phase III high-grade non-muscle invasive bladder cancer (NMIBC) trial.
-
The typical way for a biotech to launch is for a scientist, often academia-based, to have come up with a discovery that shows commercial promise—sometimes rather far down the line. Venture capital (VC) firms are on the alert for this type of thing (and vice versa).
-
Dova Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) approved its Doptelet (avatrombopag) to treat thrombocytopenia in adults with chronic liver disease scheduled to undergo a procedure.
-
Celgne's head of business development, George Golumbeski, has also left the company.
-
Allergan has exercised an option to acquire an oral small molecule compound from Illinois-based Aptinyx, a spinout of Naurex, Inc., which the Irish company acquired in 2015. The company will use it as a complement to a Phase III depression treatment.
-
Hemophilia B patients have some good news to cheer. Data suggests that uniQure’s AAV5 gene therapy may be viable treatments for 97 percent of patients. However, uniQure wasn’t the only company touting positive news in the treatment of hemophilia.
-
Aerpio Announces Initiation of Dosing in a Phase 1a, Multiple-Ascending Dose Study of AKB-4924, a Hypoxia-Inducible Factor-1 Alpha Stabilizer in Development for Inflammatory Bowel Disease
5/22/2018
AKB-4924 is a once-daily, oral, gut-restricted HIF-1 alpha stabilizer that has been shown to improve disease indices in multiple models of inflammatory bowel disease.
-
Serametrix MDSC Assay Being Utilized By Infinity Pharmaceuticals in the First Clinical Study to Prospectively Identify Patients With High Blood Levels of MDSCs
5/22/2018
First Patient Enrolled in IPI-549 Plus OPDIVO® MDSC-High Cohort in Infinity Pharmaceuticals Ongoing IPI-549-01 Phase 1/1b Clinical Trial
-
BioMarin Provides 2 Years of Clinical Data in 6e13 vg/kg Dose from Ongoing Phase 1/2 Study in Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A at World Federation of Hemophilia 2018 World Congress
5/22/2018
Eliminated Need for Prophylaxis and No Spontaneous Bleeds in Year 2 Quality of Life Scores Continue to Increase in Year 2
-
Dr. Reddy’s Q4 and FY18 Financial Results
5/22/2018
Dr. Reddy's Laboratories, Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY) today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2018 under International Financial Reporting Standards (IFRS).
-
Immunocore to Present New Data from IMCgp100-102 Trial in Metastatic Uveal Melanoma at 2018 ASCO Annual Meeting
5/22/2018
Immunocore Limited, a leading T cell receptor (TCR) company focused on delivering first-in-class biological therapies that have the potential to transform lives, today announces that new data from its phase I/II dose escalation trial of its wholly-owned, lead programme, IMCgp100, in metastatic uveal melanoma (mUM) will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on 4 June 2018.
-
SomaGenics Launches Its RealSeq®-biofluids Kit and Advances Liquid Biopsy Development With New NIH Funding for cf-miRNA NGS Technology
5/22/2018
SomaGenics announced the launch of RealSeq®-biofluids, a next-generation sequencing (NGS) library construction kit sensitive enough to detect small RNAs from cell-free biofluids. Further enhancing its efforts in the liquid biopsy arena, SomaGenics has received a 3-year Phase II SBIR grant from the NIH for the development of RealSeq®-T, a technology enabling extraction-free, targeted NGS of small RNAs directly from biofluids.
-
Monarch Biosciences Announces Fred Hutch Exclusive License and Presentations at BIO Regarding Cell Therapy Delivery Technology
5/22/2018
- Company to give two presentations at BIO International Convention in Boston June 4th - 7th, 2018: (i) Start-Up Stadium Finalist Presentation - Tuesday, June 5th from 3:15 - 3:30, Boston Convention Center, North Lobby; (ii) Company Presentation - Wednesday, June 6th from 2:15 - 2:30, Boston Convention Center, Theater 1 - Presentations to focus on dramatic increase in efficacy of locally-delivered cell therapies targeting solid tumors in preclinical models
-
QIAGEN Welcomes WHO’s Essential Diagnostics List Which Includes QuantiFERON-TB Gold
5/22/2018
The World Health Organization recommends IGRA tests in the First Edition of Essential In Vitro Diagnostics
-
The Prevalence of Childhood Poverty is Not Well Understood by Many Americans, New Survey Shows
5/22/2018
New Walgreens survey aims to raise childhood poverty awareness in advance of Red Nose Day in the U.S., May 24